| Name | Title | Contact Details |
|---|
Natura Bisse International is a Irving, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
t+ Medical Americas is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
eStudySite is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Care New England Health System (CNE) and its member institutions—Butler Hospital, Women & Infants Hospital, Kent Hospital, Memorial Hospital, VNA of Care New England, The Providence Center and Care New England Wellness Center—are trusted organizations fueling the latest advances in medical research, attracting the nation`s top specialty-trained doctors, and honing renowned services and innovative programs to engage in the important discussions people need to have about their health. Backed by a broad range of services—primary care, surgery, cardiovascular care, oncology, psychiatry, behavioral health, newborn pediatrics and the full spectrum of women`s health services—CNE is reinventing the way health care is delivered, partnering with our patients to provide the best care possible while working to create a community of healthier people. To that end, we are committed to a culture of accountability, caring and teamwork. We called it ACT values. These values were not defined by senior management but through a comprehensive process with our employees who identified these values as tangible and important to the cohesiveness of the entire organization. They are embedded into everything we do, working with patients and their families, and with each other.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.